查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916941

銀屑病生物相似藥市場按產品類型、給藥途徑、分銷管道和最終用戶分類－2026-2032年全球預測

Psoriasis Biosimilar Market by Product Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乾癬生物類似藥市場價值將達到 89.7 億美元，到 2026 年將成長至 97.4 億美元，到 2032 年將達到 188.8 億美元，複合年成長率為 11.22%。

關鍵市場統計數據
基準年 2025 89.7億美元
預計年份：2026年 97.4億美元
預測年份 2032 188.8億美元
複合年成長率 (%) 11.22%

本文全面概述了當前科學、監管和商業性趨勢如何重塑銀屑病生物相似藥市場，以及對相關人員策略的實際影響。

銀屑病生物相似藥的市場環境正處於一個轉折點，科學成熟度、監管發展和商業性趨勢的轉變交織在一起，為生產商、支付方、醫療服務提供者和患者帶來了機會和風險。分析表徵、生產製程控制和真實世界證據的進步，增強了臨床醫生和監管機構對生物相似藥療法的信心，他們相信生物相似藥療法能夠複製原研生物製藥的臨床療效，同時為長期疾病管理提供更具競爭力的選擇。同時，支付方和採購機構正在改進合約評估方式，以評估已證實的治療等效性和成本效益，並將產品差異化置於單價之外的策略重點。

在整個銀屑病生物相似藥生態系統中，推動治療可及性、生產靈活性和競爭差異化的變革需要綜合策略應對。

過去幾年，變革性的變化重新定義了銀屑病生物相似藥的研發、核准和應用方式。調查方法和過程分析技術的進步降低了免疫抗原性和結構可比性的不確定性，使許多地區的臨床試驗得以縮短，並提高了跨適應症外推的可行性。同時，法規結構日趨成熟，監管機構更加重視健全的藥物監測、可追溯性和核准後證據的生成。這促使業界加大對真實世界資料系統和病患登記系統的投入，以證明藥物的長期安全性和有效性。

評估美國2025年實施的累積關稅變化及其對供應鏈韌性、價格談判和策略性製造選擇的多方面影響

美國將於2025年實施的新關稅政策，為銀屑病生物相似藥領域的企業帶來了一系列重要的營運和商業考量。關稅調整會影響國際供應鏈的經濟效益，改變活性藥物成分、生物製藥和成品的採購和生產地點獎勵。對於依賴跨境原料流動或第三方生產的開發商而言，關稅政策凸顯了供應鏈圖譜繪製、劑量成本敏感性分析以及與合約研發生產機構（CDMO）簽訂合約保障措施的重要性。因此，許多企業正在加速在地化策略的實施，並實現供應鏈多元化，以降低單一國家貿易中斷的風險。

針對特定細分市場的洞察分析揭示了產品類型、給藥途徑、分銷管道和最終用戶特徵如何決定生物相似藥的採用模式和臨床應用。

在乾癬生物類似藥領域，細分市場的特定趨勢塑造了產品推廣路徑和競爭重點，而產品類型的差異決定了臨床定位和研發重點。此領域可細分為融合蛋白和單株抗體兩大類。融合蛋白類包括Etanercept生物相似藥，而單株抗體類包括Adalimumab單抗生物相似藥和Infliximab單抗生物相似藥。每類產品都面臨獨特的生產挑戰和推廣應用的考量，這些都會影響監管策略和臨床醫生的信心。給藥途徑也是一個重要因素，靜脈注射和皮下注射在供應鏈需求、病患支持需求和醫護人員培訓需求方面存在差異。靜脈注射製劑通常與醫院輸液服務相匹配，其低溫運輸和給藥成本與皮下注射製劑不同，後者更適合社區和居家醫療。

區域觀點：分析美洲、歐洲、中東和非洲以及亞太地區的需求促進因素、報銷架構和基礎設施差異。

區域在報銷、監管實踐和醫療基礎設施方面的差異對銀屑病生物相似藥的推廣和規模有顯著影響。在美洲，從單一支付方的州級體係到公私混合市場，各醫療體系的差異化要求採取不同的支付方參與策略、競標方式和臨床醫生教育，以支持生物類似藥的推廣應用。在歐洲、中東和非洲，雖然部分地區的生物相似藥核准途徑法規環境較為統一，但在其他地區，准入挑戰和採購方式的差異依然存在，因此區域夥伴關係和本地市場證據的收集是成功策略的關鍵要素。在亞太地區，區域客製化的臨床數據和患者支援模式日益重要，這反映了該地區法規結構的多樣性和快速發展、多個國家強大的國內生產能力以及不同的報銷和分銷基礎設施。

開發商、製造商和專業經銷商之間的競爭格局和聯盟考量，正在塑造銀屑病生物類似藥的競爭格局和市場進入趨勢。

銀屑病生物相似藥領域的競爭格局由成熟的生物製藥生產商、專業的生物相似藥開發商、契約製造生產商和分銷商組成。領先企業憑藉其生產規模、成熟的監管能力以及在上市後核准建立方面的投入脫穎而出，從而贏得醫療服務提供者和支付方的信任。策略聯盟、授權協議和共同開發契約十分常見，這些協議能夠實現技術轉移、本地市場准入和共用商業基礎設施，從而加快產品上市速度並降低單一方承擔的監管風險。合約開發和生產組織 (CDMO) 在產能擴張和風險分擔方面發揮關鍵作用，它們提供模組化能力以支援快速上市和靈活的供應承諾。

在生物相似藥時代變革中，為產業領導者提供切實可行的建議，以協調研發實力、生產韌性、商業性差異化和支付方合作。

產業領導者應優先考慮一系列整合科學可信度、商業性可行性和營運韌性的措施。首先，投資於嚴謹的可比較性資料包和核准後證據生成，以明確解決臨床醫生和支付方對安全性、可替代性和長期療效的擔憂。其次，設計以靈活的生產能力、區域中心和雙重採購為重點的生產策略，以確保供應穩定，同時減輕貿易政策波動和關稅相關成本壓力的影響。第三，採用差異化的商業模式，將具有競爭力的價格與附加價值服務（例如病患支援、依從性計畫和療效監測）結合，從而將支付方的關注點從單位成本轉移到總醫療成本。

調查方法和資料來源的透明度，包括對基礎資料來源、分析框架、檢驗程序以及銀屑病生物類似藥策略分析限制的解釋

本分析採用三角驗證研究途徑，整合多面向證據，旨在確保其可靠性和實際應用價值。調查方法包括：系統性回顧監管指南、同行評審的生物製藥可比性和免疫抗原性文獻、分析公開文件和採購機制，以及與臨床、生產和市場進入專家進行結構化訪談，以驗證檢驗並識別執行風險。數據綜合分析著重探討不同司法管轄區的監管趨勢、生產和供應鏈的實際情況，以及商業性實施的經驗性見解，從而確定能夠顯著影響推廣率和市場韌性的策略槓桿。

總結而言，本文對銀屑病生物相似藥在科學、監管、分銷和患者獲取方面的新興趨勢進行了綜合分析，並探討了其對相關人員。

總之，銀屑病生物相似藥市場正從概念驗證階段邁向營運卓越、策略夥伴關係和實證商業模式將決定其持續成功的階段。儘管科學和監管方面的進步降低了准入門檻，但市場接受度仍然不均衡，並將取決於企業能否將生產可靠性、區域市場進入計劃和核准後證據整合到一個連貫的價值提案中。貿易政策和關稅的變化帶來了額外的營運複雜性，凸顯了靈活的生產和供應鏈策略的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 銀屑病生物相似藥市場（依產品類型分類）

  • 融合蛋白
  • 單株抗體
    • Adalimumab生物相似藥
    • Infliximab生物類似藥

9. 銀屑病生物相似藥市場依給藥途徑分類

  • 靜脈注射
  • 皮下注射

10. 銀屑病生物相似藥市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 銀屑病生物相似藥市場（依最終用戶分類）

  • 診所
  • 醫院
  • 專業皮膚病中心

12. 銀屑病生物相似藥市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 銀屑病生物相似藥市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國銀屑病生物相似藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章美國銀屑病生物相似藥市場

第16章：中國銀屑病生物相似藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Stada Arzneimittel AG
  • Viatris, Inc.
Product Code: MRR-AE420CB1540B

The Psoriasis Biosimilar Market was valued at USD 8.97 billion in 2025 and is projected to grow to USD 9.74 billion in 2026, with a CAGR of 11.22%, reaching USD 18.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.97 billion
Estimated Year [2026] USD 9.74 billion
Forecast Year [2032] USD 18.88 billion
CAGR (%) 11.22%

A comprehensive introduction outlining the current scientific, regulatory, and commercial dynamics reshaping psoriasis biosimilars and practical implications for stakeholder strategies

The psoriasis biosimilar landscape sits at an inflection point where scientific maturity, regulatory evolution, and shifting commercial dynamics intersect to create both risk and opportunity for manufacturers, payers, providers, and patients. Advances in analytical characterization, manufacturing process control, and real-world evidence generation have increased confidence among clinicians and regulators that biosimilar therapies can replicate the clinical performance of originator biologics while offering competitive options for long-term disease management. At the same time, payers and procurement bodies are evolving their contracting approaches to reward demonstrated therapeutic equivalence and cost-effectiveness, which places strategic emphasis on product differentiation beyond unit price.

Operationally, developers must navigate complex biologics manufacturing and supply-chain constraints while aligning clinical development strategies to local regulatory expectations that continue to converge but remain heterogeneous across jurisdictions. Commercial teams are rethinking brand positioning and provider engagement, emphasizing dossier completeness, outcomes data, and patient support mechanisms to accelerate uptake. As stakeholders reassess risk tolerances and investment priorities, clear alignment across R&D, regulatory, manufacturing, and commercial functions becomes essential to convert scientific capability into sustained market access and patient benefit. This introduction frames the analysis that follows, focusing on the practical considerations organizations must address to succeed in this rapidly maturing therapeutic category.

Transformative shifts driving therapeutic access, manufacturing agility, and competitive differentiation across the psoriasis biosimilar ecosystem that demand integrated strategic responses

Over the past several years, transformative shifts have redefined how psoriasis biosimilars are developed, approved, and adopted. Technological advancements in analytical methodologies and process analytics have reduced residual uncertainty around immunogenicity and structural comparability, enabling abbreviated clinical pathways in many jurisdictions and increasing the feasibility of extrapolation across indications. Concurrently, regulatory frameworks have matured, with agencies emphasizing robust pharmacovigilance, traceability, and post-approval evidence generation, which has in turn shaped industry investment into real-world data systems and patient registries to demonstrate long-term safety and effectiveness.

Commercially, competitive differentiation has moved beyond price alone toward evidence-based value propositions that include manufacturing reliability, supply security, patient support services, and outcomes-based contracting. Manufacturing scale-up strategies emphasize flexible facilities and modular process designs to mitigate capacity constraints and accelerate technology transfer. Market access dynamics are also shifting as payers and health systems prioritize therapeutic interchange policies and value-based procurement approaches that reward suppliers capable of delivering measurable clinical and economic outcomes. Taken together, these shifts compel companies to integrate scientific robustness with commercial agility, aligning internal capabilities to navigate complex stakeholder expectations and seize opportunities in a landscape where clinical equivalence must be matched by demonstrable system-level value.

Assessment of cumulative United States tariff changes in 2025 and their multidimensional effects on supply chain resilience, pricing negotiations, and strategic manufacturing choices

The introduction of new tariffs in the United States in 2025 has introduced a material set of operational and commercial considerations for actors in the psoriasis biosimilar arena. Tariff adjustments affect the economics of international supply chains, altering incentives for where active pharmaceutical ingredients, biologics drug substances, and finished products are sourced and manufactured. For developers reliant on cross-border raw material flows or on third-party manufacturing, tariffs increase the importance of supply-chain mapping, cost-per-dose sensitivity analysis, and contractual safeguards with contract development and manufacturing organizations. As a result, many organizations have responded by accelerating localization strategies or diversifying supplier bases to reduce exposure to single-country trade disruptions.

Beyond cost impacts, tariffs have implications for pricing strategy and payer negotiations. Procurement organizations may demand clearer evidence of total cost of care and supply resilience as part of contracting discussions, and manufacturers may need to offer more robust risk-sharing or bundled contracting solutions to maintain formulary access. Clinical trial logistics are also affected where investigational product imports and clinical supplies cross tariff boundaries, necessitating proactive customs planning and regulatory filings. Finally, trade policy uncertainty has increased the premium on flexible commercial models, including multi-sourcing, regional manufacturing hubs, and enhanced inventory management, all intended to insulate patients and providers from intermittent supply volatility while preserving long-term strategic options.

Segment-specific insights decoding how product types, administration routes, distribution channels, and end-user profiles will determine adoption patterns and clinical uptake for biosimilars

Segment-specific dynamics will shape adoption pathways and competitive focus areas across the psoriasis biosimilar sector, with product-type distinctions driving clinical positioning and development priorities. The landscape differentiates between fusion proteins and monoclonal antibodies, where the fusion proteins segment includes etanercept biosimilars and the monoclonal antibodies segment encompasses adalimumab biosimilars and infliximab biosimilars; each category presents distinct manufacturing control challenges and extrapolation considerations that influence regulatory strategies and clinician confidence. Route of administration is another critical axis, where intravenous administration and subcutaneous administration impose different supply chain requirements, patient support needs, and provider training imperatives; intravenous formulations often align with hospital-based infusion services and have different cold-chain and administration cost profiles compared with subcutaneous options suitable for community or home use.

Distribution channel segmentation further defines commercial execution plans, with hospital pharmacy, online pharmacy, and retail pharmacy each requiring tailored contracting models, patient access programs, and reimbursement approaches. End-user segmentation, spanning clinics, hospitals, and specialty dermatology centers, dictates where education, sample programs, and clinical liaison resources should be concentrated to influence prescribing behavior and optimize continuity of care. Strategic choices around which segments to prioritize will depend on a company's manufacturing footprint, logistical competencies, and commercial channel capabilities, and successful players will align clinical evidence packages, service offerings, and distribution arrangements to the operational realities and decision-making processes of each segment.

Regional perspectives dissecting demand drivers, reimbursement frameworks, and infrastructure variations across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional nuances in reimbursement, regulatory practice, and healthcare infrastructure critically influence how psoriasis biosimilars are introduced and scaled. In the Americas, systems range from single-payer provincial frameworks to mixed public-private markets, requiring differentiated payer engagement strategies, tendering approaches, and clinician education to support biosimilar uptake. In Europe, Middle East & Africa the regulatory environment often exhibits greater harmonization for biosimilar pathways in some subregions while access challenges and procurement variability persist in others, making regional partnerships and local-market evidence generation important components of a successful strategy. Asia-Pacific presents a heterogeneous mix of rapidly evolving regulatory frameworks, strong domestic manufacturing capabilities in several countries, and growing emphasis on localized clinical data and patient-assistance models that reflect varied reimbursement and distribution infrastructures.

Across these geographies, planning for regulatory dossier alignment, pharmacovigilance networks, and supply resilience is essential. Differences in healthcare delivery models and payer levers mean that successful regional strategies combine technical evidence packages with pragmatic commercial models adapted to procurement cycles, clinical practice norms, and the local value discourse. Companies that blend global development consistency with local implementation agility-whether through regional manufacturing hubs, strategic partnerships, or targeted evidence generation-are better positioned to navigate regional complexities and accelerate patient access while maintaining operational control.

Competitive profiling and partnership considerations for developers, manufacturers, and specialty distributors shaping psoriasis biosimilar competition and market entry dynamics

Competitive dynamics in the psoriasis biosimilar space are defined by a mix of established biologics manufacturers, specialized biosimilar developers, contract manufacturers, and distribution specialists. Leading players differentiate through manufacturing scale, demonstrated regulatory track record, and investments in post-approval evidence that build clinician and payer trust. Strategic partnerships, licensing agreements, and co-development arrangements are common, enabling technology transfer, local market entry, and shared commercial infrastructure that reduces time-to-market and mitigates single-party exposure to regulatory risk. Contract development and manufacturing organizations play a crucial role in capacity expansion and risk sharing, offering modular capabilities that support accelerated launches and flexible supply commitments.

Commercial differentiation increasingly relies on integrated service offerings that go beyond the molecule to include patient support programs, injection training, adherence monitoring, and real-world outcome tracking. Specialty distributors and pharmacy networks that can ensure cold-chain integrity and timely delivery to hospital pharmacies, retail outlets, and online fulfillment channels are essential to maintaining clinician confidence. Intellectual property strategies, portfolio breadth across etanercept, adalimumab, and infliximab biosimilars, and a clear record of regulatory approvals also shape competitive positioning. Market entrants that combine robust technical capability with pragmatic commercialization and partnership models tend to achieve greater acceptance in complex procurement environments where evidence of operational reliability and cost of care impact informs payer and provider decisions.

Actionable recommendations for industry leaders to align R&D robustness, manufacturing resilience, commercial differentiation, and payer engagement in a changing biosimilar era

Industry leaders should prioritize an integrated set of actions that align scientific credibility with commercial execution and operational resilience. First, invest in rigorous comparability packages and post-approval evidence generation that demonstrably address clinician and payer concerns about safety, interchangeability, and long-term outcomes. Second, design manufacturing strategies that emphasize flexible capacity, regional hubs, and dual-sourcing to mitigate trade policy shocks and tariff-related cost pressures while ensuring consistent supply. Third, adopt differentiated commercial models that combine competitive pricing with value-added services such as patient support, adherence programs, and outcomes monitoring, thereby shifting conversations with payers from unit price to total cost of care.

Additionally, strengthen payer and provider engagement through early, evidence-driven dialogue and tailored value dossiers that reflect local reimbursement criteria and procurement cycles. Build partnerships with specialty distributors and clinical sites to ensure seamless administration across intravenous and subcutaneous channels, and invest in digital platforms that support remote patient management and data capture. Finally, embed scenario planning into strategic decision-making to anticipate policy and trade changes, and align internal governance to enable rapid reallocation of resources in response to regulatory or supply-chain disruptions. Acting across these dimensions will help organizations convert technical capability into sustained market access and durable clinical adoption.

Methodological transparency explaining data sources, analytical frameworks, validation steps, and limitations that underpin the psoriasis biosimilar strategic analysis

This analysis synthesizes multiple evidence streams using a triangulated research approach designed to ensure reliability and practical relevance. The methodology combined systematic review of regulatory guidance, peer-reviewed literature on biologics comparability and immunogenicity, analysis of public filings and procurement mechanisms, and structured interviews with clinical, manufacturing, and market access experts to validate assumptions and surface execution risks. Data synthesis emphasized cross-jurisdictional regulatory trends, manufacturing and supply-chain realities, and experiential insights from commercial launches to identify strategic levers that materially affect uptake and resilience.

Validation steps included iterative review with subject-matter experts, scenario testing of supply-chain and tariff sensitivities, and cross-checking of claims against regulatory guidance documents and clinical evidence where available. Limitations of the methodology are acknowledged: evolving regulatory policies and trade measures can change the operating environment after publication, and some proprietary commercial data was not accessible for confidentiality reasons. To mitigate these constraints, the report focuses on actionable qualitative insights and decision frameworks rather than numerical market projections, enabling readers to apply the findings to their own internal data and strategic plans.

Concluding synthesis tying strategic implications for stakeholders to emergent trends in science, regulation, distribution, and patient access for psoriasis biosimilars

In conclusion, the psoriasis biosimilar landscape is transitioning from a proof-of-concept era into a phase where operational excellence, strategic partnerships, and evidence-based commercial models determine sustainable success. Scientific and regulatory progress has lowered barriers to entry, but adoption will be uneven and driven by an organization's ability to integrate manufacturing reliability, localized market access planning, and post-approval evidence into a coherent value proposition. Trade policies and tariff changes introduce additional operational complexity that elevates the importance of flexible manufacturing and supply-chain strategies.

Stakeholders who proactively align internal capabilities-spanning comparability science, scalable manufacturing, payer engagement, and patient support-will be positioned to convert technical equivalence into meaningful clinical and economic outcomes. The path forward emphasizes disciplined execution, adaptive commercial models, and investment in evidence generation that resonates with clinicians and payers. Ultimately, success in this therapeutic segment will rest on the ability to deliver consistent clinical performance at scale while addressing the systemic levers that influence access and long-term adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Biosimilar Market, by Product Type

  • 8.1. Fusion Proteins
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Adalimumab Biosimilars
    • 8.2.2. Infliximab Biosimilars

9. Psoriasis Biosimilar Market, by Route Of Administration

  • 9.1. Intravenous Administration
  • 9.2. Subcutaneous Administration

10. Psoriasis Biosimilar Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Psoriasis Biosimilar Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Specialty Dermatology Centers

12. Psoriasis Biosimilar Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Psoriasis Biosimilar Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Psoriasis Biosimilar Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Psoriasis Biosimilar Market

16. China Psoriasis Biosimilar Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. Biocon Ltd.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Celltrion, Inc.
  • 17.9. Coherus BioSciences, Inc.
  • 17.10. Fresenius Kabi
  • 17.11. Pfizer Inc.
  • 17.12. Samsung Bioepis Co., Ltd.
  • 17.13. Sandoz International GmbH
  • 17.14. Stada Arzneimittel AG
  • 17.15. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS BIOSIMILAR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PSORIASIS BIOSIMILAR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY SPECIALTY DERMATOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PSORIASIS BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PSORIASIS BIOSIMILAR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)